UK Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at the start of the year, Miels then ripped up his own rule book with the USD 10.6 billion acquisition of…
Hong Kong When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed. The legitimate questions of what this updated regulator would do, and whom it would serve, swirled, with many Western multinationals…
Hong Kong In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to groundbreaking early-stage work in vaccines, oncology, and even cell therapy, as well as some later-stage studies for niche indications, both…
Taiwan Tina Graves, General Manager of GSK Taiwan, reflects on the affiliate’s strong commercial performance, the strategic shift towards specialty care and oncology, and the urgent case for repositioning adult immunisation as a public health investment. She outlines how Taiwan can become a clinical trial powerhouse, and describes a leadership philosophy…
Hong Kong GSK Hong Kong’s first year under Nicholas Teo marks a period of rapid evolution in the city’s healthcare system, from the strengthening of primary care to a deeper reliance on real world evidence and closer collaboration across government, academia and insurers. The affiliate is advancing a balanced portfolio in specialty…
Global In a pharma industry increasingly squeezed by falling legacy revenues, political pricing crackdowns, and the need to deliver the next wave of science at speed and scale, the right leadership is crucial. Four of the Top 25 global pharma companies – Novo Nordisk (ranked 10th), GSK (12th), Takeda (14th), and…
China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…
China A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun and Expedition Therapeutics ink respiratory licensing deal, and GSK lands USD 500 million 12-drug agreement with Hengrui Pharma. China…
UK A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian biotech EsoBiotec and its exit from neuroscience; GSK’s liver disease asset deal with Boston Pharmaceuticals, and CellCentric’s US expansion. …
Global Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies, and examining the broader trends shaping the industry. Here is a selection of some of the year’s most-read interviews. …
Global The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs). Novartis tops the ranking – based on a wide-ranging assessment of access governance, R&D, and product delivery – meaning that…
USA The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win by Republican Donald Trump. “When it comes to elections we work with governments of all stripes everywhere,” Walmsley assured. With…
See our Cookie Privacy Policy Here
